JP2019509286A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019509286A5 JP2019509286A5 JP2018546864A JP2018546864A JP2019509286A5 JP 2019509286 A5 JP2019509286 A5 JP 2019509286A5 JP 2018546864 A JP2018546864 A JP 2018546864A JP 2018546864 A JP2018546864 A JP 2018546864A JP 2019509286 A5 JP2019509286 A5 JP 2019509286A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- crystalline form
- form according
- chloro
- biphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 12
- 238000000034 method Methods 0.000 claims 11
- -1 5'-Chloro-2'-fluoro- [1,1'-biphenyl] -4-yl Chemical group 0.000 claims 7
- 206010020772 Hypertension Diseases 0.000 claims 7
- 208000017169 kidney disease Diseases 0.000 claims 6
- 239000002904 solvent Substances 0.000 claims 6
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 5
- 239000006186 oral dosage form Substances 0.000 claims 5
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 claims 4
- 101800001288 Atrial natriuretic factor Proteins 0.000 claims 4
- 101800001890 Atrial natriuretic peptide Proteins 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 4
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 claims 4
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 239000007822 coupling agent Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 108010010803 Gelatin Proteins 0.000 claims 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical group CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- 229920000159 gelatin Polymers 0.000 claims 2
- 239000008273 gelatin Substances 0.000 claims 2
- 235000019322 gelatine Nutrition 0.000 claims 2
- 235000011852 gelatine desserts Nutrition 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 229920001059 synthetic polymer Polymers 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- DSIBSRXKQRYPJP-UHFFFAOYSA-N 1,2-oxazole-5-carboxamide Chemical compound NC(=O)C1=CC=NO1 DSIBSRXKQRYPJP-UHFFFAOYSA-N 0.000 claims 1
- MXNFUCNDPLBTMF-UHFFFAOYSA-N 1,3-oxazole-5-carboxamide Chemical compound NC(=O)C1=CN=CO1 MXNFUCNDPLBTMF-UHFFFAOYSA-N 0.000 claims 1
- UIMYDHSKYAJZRW-UHFFFAOYSA-N 3-[(4-methoxyphenyl)methoxy]-1,2-oxazole-5-carboxylic acid Chemical compound C1=CC(OC)=CC=C1COC1=NOC(C(O)=O)=C1 UIMYDHSKYAJZRW-UHFFFAOYSA-N 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 208000026151 Chronic thromboembolic pulmonary hypertension Diseases 0.000 claims 1
- ONEZSVGPOIYCQE-CCUCXNRWSA-N Cl.N[C@@H](C[C@@](C(=O)OCC1=CC=CC=C1)(C)COCC)CC1=CC=C(C=C1)C1=C(C=CC(=C1)Cl)F Chemical compound Cl.N[C@@H](C[C@@](C(=O)OCC1=CC=CC=C1)(C)COCC)CC1=CC=C(C=C1)C1=C(C=CC(=C1)Cl)F ONEZSVGPOIYCQE-CCUCXNRWSA-N 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000007530 Essential hypertension Diseases 0.000 claims 1
- 229940094419 Guanylate cyclase inhibitor Drugs 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 208000004531 Renal Artery Obstruction Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010038378 Renal artery stenosis Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 claims 1
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 229940083712 aldosterone antagonist Drugs 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 1
- 230000024924 glomerular filtration Effects 0.000 claims 1
- 239000003126 guanylate cyclase inhibitor Substances 0.000 claims 1
- 239000007902 hard capsule Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000002394 mineralocorticoid antagonist Substances 0.000 claims 1
- 229910052763 palladium Inorganic materials 0.000 claims 1
- 238000005897 peptide coupling reaction Methods 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
- 239000002798 polar solvent Substances 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 201000001474 proteinuria Diseases 0.000 claims 1
- 210000001147 pulmonary artery Anatomy 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 239000002516 radical scavenger Substances 0.000 claims 1
- 239000002461 renin inhibitor Substances 0.000 claims 1
- 229940086526 renin-inhibitors Drugs 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021177448A JP2022017433A (ja) | 2016-03-08 | 2021-10-29 | 結晶性（２ｓ，４ｒ）－５－（５’－クロロ－２’－フルオロ－［１，１’－ビフェニル］－４－イル）－２－（エトキシメチル）－４－（３－ヒドロキシイソオキサゾール－５－カルボキサミド）－２－メチルペンタン酸およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662305393P | 2016-03-08 | 2016-03-08 | |
| US62/305,393 | 2016-03-08 | ||
| US201662346336P | 2016-06-06 | 2016-06-06 | |
| US62/346,336 | 2016-06-06 | ||
| PCT/US2017/021172 WO2017156009A1 (en) | 2016-03-08 | 2017-03-07 | Crystalline(2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021177448A Division JP2022017433A (ja) | 2016-03-08 | 2021-10-29 | 結晶性（２ｓ，４ｒ）－５－（５’－クロロ－２’－フルオロ－［１，１’－ビフェニル］－４－イル）－２－（エトキシメチル）－４－（３－ヒドロキシイソオキサゾール－５－カルボキサミド）－２－メチルペンタン酸およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019509286A JP2019509286A (ja) | 2019-04-04 |
| JP2019509286A5 true JP2019509286A5 (cg-RX-API-DMAC7.html) | 2020-04-02 |
| JP7306828B2 JP7306828B2 (ja) | 2023-07-11 |
Family
ID=58387911
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018546864A Active JP7306828B2 (ja) | 2016-03-08 | 2017-03-07 | 結晶性（２ｓ，４ｒ）－５－（５’－クロロ－２’－フルオロ－［１，１’－ビフェニル］－４－イル）－２－（エトキシメチル）－４－（３－ヒドロキシイソオキサゾール－５－カルボキサミド）－２－メチルペンタン酸およびその使用 |
| JP2021177448A Pending JP2022017433A (ja) | 2016-03-08 | 2021-10-29 | 結晶性（２ｓ，４ｒ）－５－（５’－クロロ－２’－フルオロ－［１，１’－ビフェニル］－４－イル）－２－（エトキシメチル）－４－（３－ヒドロキシイソオキサゾール－５－カルボキサミド）－２－メチルペンタン酸およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021177448A Pending JP2022017433A (ja) | 2016-03-08 | 2021-10-29 | 結晶性（２ｓ，４ｒ）－５－（５’－クロロ－２’－フルオロ－［１，１’－ビフェニル］－４－イル）－２－（エトキシメチル）－４－（３－ヒドロキシイソオキサゾール－５－カルボキサミド）－２－メチルペンタン酸およびその使用 |
Country Status (30)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10100021B2 (en) | 2016-03-08 | 2018-10-16 | Theravance Biopharma R&D Ip, Llc | Crystalline(2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof |
| JP7316449B2 (ja) * | 2019-09-20 | 2023-07-27 | シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッド | 心不全治療におけるアンジオテンシンｉｉ受容体アンタゴニスト代謝産物とｎｅｐ阻害剤との複合体の使用 |
| KR102485499B1 (ko) * | 2022-07-15 | 2023-01-09 | 오가노이드사이언스 주식회사 | 신장 질환의 치료 또는 예방용 조성물 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4189604A (en) | 1975-07-22 | 1980-02-19 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Bestatin |
| US4206232A (en) | 1976-05-10 | 1980-06-03 | E. R. Squibb & Sons, Inc. | Relieving hypertension with carboxyalkylacylamino acids |
| IL58849A (en) | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
| FR2480747A1 (fr) | 1980-04-17 | 1981-10-23 | Roques Bernard | Derives d'acides amines et leur application therapeutique |
| US4906615A (en) | 1980-12-18 | 1990-03-06 | Schering Corporation | Substituted dipeptides as inhibitors of enkephalinases |
| US4722810A (en) | 1984-08-16 | 1988-02-02 | E. R. Squibb & Sons, Inc. | Enkephalinase inhibitors |
| US4939261A (en) | 1984-06-08 | 1990-07-03 | Ciba-Geigy Corporation | N-substituted butyramide derivatives useful for treatment of conditions responsive to inhibition of enkephalinase |
| EP0225292A3 (en) | 1985-12-06 | 1988-11-30 | Ciba-Geigy Ag | Certain n-substituted butyramide derivatives |
| US4929641B1 (en) | 1988-05-11 | 1994-08-30 | Schering Corp | Mercapto-acylamino acid antihypertensives |
| KR880007441A (ko) | 1986-12-11 | 1988-08-27 | 알렌 제이.스피겔 | 스피로-치환된 글루타르아미드 이뇨제 |
| FR2623498B1 (fr) | 1987-11-24 | 1990-04-06 | Bioprojet Soc Civ | Nouveaux composes enantiomeres derives d'amino-acides, leur procede de preparation et leurs applications therapeutiques |
| GB8820844D0 (en) | 1988-09-05 | 1988-10-05 | Pfizer Ltd | Therapeutic agents |
| US5599951A (en) | 1989-09-15 | 1997-02-04 | Societe Civile Bioprojet | Amino acid derivatives, the process for their preparation and their applications to therapy |
| US5294632A (en) | 1991-05-01 | 1994-03-15 | Ciba-Geigy Corporation | Phosphono/biaryl substituted dipetide derivatives |
| US5155100A (en) | 1991-05-01 | 1992-10-13 | Ciba-Geigy Corporation | Phosphono/biaryl substituted dipeptide derivatives |
| US5217996A (en) | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
| US5508272A (en) | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
| DE19510566A1 (de) | 1995-03-23 | 1996-09-26 | Kali Chemie Pharma Gmbh | Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| EP0821670A1 (en) | 1995-04-21 | 1998-02-04 | Novartis AG | N-aroylamino acid amides as endothelin inhibitors |
| US6660756B2 (en) | 2001-03-28 | 2003-12-09 | Pfizer Inc. | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
| GB0119305D0 (en) | 2001-04-12 | 2001-10-03 | Aventis Pharma Gmbh | Mercaptoacetylamide derivatives,a process for their preparation and their use |
| WO2006027680A1 (en) | 2004-09-10 | 2006-03-16 | Pfizer Limited | 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| US20070204367A1 (en) | 2006-02-17 | 2007-08-30 | Stanislaw Flasinski | Chimeric regulatory sequences comprising introns for plant gene expression |
| WO2007106708A2 (en) | 2006-03-10 | 2007-09-20 | Novartis Ag | Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril |
| CA2674291C (en) | 2007-01-12 | 2015-11-24 | Novartis Ag | New process |
| TWI448284B (zh) | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
| AR070176A1 (es) | 2008-01-17 | 2010-03-17 | Novartis Ag | Procesos de sintesis de inhibidores de nep, compuestos intermediarios y uso de los mismos en la sintesis |
| EP3048100A1 (en) | 2009-05-28 | 2016-07-27 | Novartis AG | Substituted aminobutyric derivatives as neprilysin inhibitors |
| ES2523734T3 (es) * | 2009-05-28 | 2014-12-01 | Novartis Ag | Derivados aminopropiónicos sustituidos como inhibidores de neprilisina |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| ES2550485T3 (es) | 2010-01-22 | 2015-11-10 | Novartis Ag | Intermedios de inhibidores de la endopeptidasa neutra y método de preparación de los mismos |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| US8993631B2 (en) | 2010-11-16 | 2015-03-31 | Novartis Ag | Method of treating contrast-induced nephropathy |
| HRP20151115T1 (en) | 2010-12-15 | 2015-11-20 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
| BR112013014952A2 (pt) | 2010-12-15 | 2017-05-30 | Theravance Inc | inibidores de neprilisina |
| EP2675795B1 (en) * | 2011-02-17 | 2016-04-20 | Theravance Biopharma R&D IP, LLC | Substituted aminobutyric derivatives as neprilysin inhibitors |
| WO2012154249A1 (en) | 2011-02-17 | 2012-11-15 | Theravance, Inc. | Substituted aminobutyric derivatives as neprilysin inhibitors |
| EP2714660B1 (en) | 2011-05-31 | 2018-09-26 | Theravance Biopharma R&D IP, LLC | Neprilysin inhibitors |
| JP5959074B2 (ja) | 2011-05-31 | 2016-08-02 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | ネプリライシン阻害剤 |
| CN103748070B (zh) | 2011-05-31 | 2015-06-24 | 施万生物制药研发Ip有限责任公司 | 脑啡肽酶抑制剂 |
| TWI560172B (en) | 2011-11-02 | 2016-12-01 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
| CN104350052B (zh) | 2012-05-31 | 2017-05-31 | 施万生物制药研发Ip有限责任公司 | 一氧化氮供体脑啡肽酶抑制剂 |
| RS55967B1 (sr) | 2012-06-08 | 2017-09-29 | Theravance Biopharma R&D Ip Llc | Inhibitori neprilizina |
| CA2873328A1 (en) | 2012-06-08 | 2013-12-12 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
| SMT201700134T1 (it) * | 2012-08-08 | 2017-05-08 | Theravance Biopharma R&D Ip Llc | Inibitori della neprilisina |
| KR101811549B1 (ko) * | 2013-06-19 | 2017-12-26 | 에프. 호프만-라 로슈 아게 | 인돌린-2-온 또는 피롤로-피리딘/피리미딘-2-온 유도체 |
| CN105992763A (zh) * | 2014-01-30 | 2016-10-05 | 施万生物制药研发Ip有限责任公司 | 脑啡肽酶抑制剂 |
| US10100021B2 (en) | 2016-03-08 | 2018-10-16 | Theravance Biopharma R&D Ip, Llc | Crystalline(2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof |
-
2017
- 2017-03-07 US US15/452,333 patent/US10100021B2/en active Active
- 2017-03-07 EP EP17712605.9A patent/EP3408260B1/en active Active
- 2017-03-07 LT LTEP17712605.9T patent/LT3408260T/lt unknown
- 2017-03-07 ES ES17712605T patent/ES2880123T3/es active Active
- 2017-03-07 HR HRP20211169TT patent/HRP20211169T1/hr unknown
- 2017-03-07 WO PCT/US2017/021172 patent/WO2017156009A1/en not_active Ceased
- 2017-03-07 MX MX2018010727A patent/MX377177B/es active IP Right Grant
- 2017-03-07 JP JP2018546864A patent/JP7306828B2/ja active Active
- 2017-03-07 KR KR1020227008251A patent/KR20220035991A/ko not_active Ceased
- 2017-03-07 RS RS20210963A patent/RS62172B1/sr unknown
- 2017-03-07 PL PL17712605T patent/PL3408260T3/pl unknown
- 2017-03-07 SG SG11201807591VA patent/SG11201807591VA/en unknown
- 2017-03-07 KR KR1020187028757A patent/KR20180114225A/ko not_active Ceased
- 2017-03-07 AU AU2017229466A patent/AU2017229466C1/en active Active
- 2017-03-07 CA CA3015505A patent/CA3015505C/en active Active
- 2017-03-07 RU RU2018135072A patent/RU2756223C2/ru active
- 2017-03-07 DK DK17712605.9T patent/DK3408260T3/da active
- 2017-03-07 MY MYPI2018702868A patent/MY198185A/en unknown
- 2017-03-07 SI SI201730845T patent/SI3408260T1/sl unknown
- 2017-03-07 CN CN201780016076.5A patent/CN108779084A/zh active Pending
- 2017-03-07 PT PT177126059T patent/PT3408260T/pt unknown
- 2017-03-07 SM SM20210434T patent/SMT202100434T1/it unknown
- 2017-03-07 HU HUE17712605A patent/HUE055546T2/hu unknown
- 2017-03-07 TW TW106107450A patent/TWI731943B/zh active
-
2018
- 2018-08-20 IL IL261244A patent/IL261244B/en unknown
- 2018-08-30 ZA ZA2018/05840A patent/ZA201805840B/en unknown
- 2018-09-02 SA SA518392325A patent/SA518392325B1/ar unknown
- 2018-09-03 PH PH12018501876A patent/PH12018501876A1/en unknown
- 2018-09-05 CL CL2018002539A patent/CL2018002539A1/es unknown
- 2018-09-10 US US16/125,991 patent/US10472335B2/en active Active
- 2018-10-02 CO CONC2018/0010568A patent/CO2018010568A2/es unknown
-
2019
- 2019-09-25 US US16/582,051 patent/US10752599B2/en active Active
-
2020
- 2020-07-14 US US16/928,206 patent/US11230536B2/en active Active
-
2021
- 2021-07-30 CY CY20211100685T patent/CY1124397T1/el unknown
- 2021-10-29 JP JP2021177448A patent/JP2022017433A/ja active Pending
- 2021-12-14 US US17/550,564 patent/US11718591B2/en active Active
-
2024
- 2024-02-15 US US18/442,885 patent/US12351561B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6634368B2 (ja) | 複素環式化合物及びそれらの使用 | |
| JPH02295978A (ja) | フェニルピリミドン誘導体 | |
| ES2972295T3 (es) | Sales de 2-(tert-butilamino)-4-((1R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-pirimidin-5-carboxamida | |
| JP2009084270A (ja) | 塩形態 | |
| JP2019509286A5 (cg-RX-API-DMAC7.html) | ||
| JP2019501216A5 (cg-RX-API-DMAC7.html) | ||
| TW200827326A (en) | Organic compounds | |
| JP2010516702A5 (cg-RX-API-DMAC7.html) | ||
| TW201720444A (zh) | 含有2-{4-[n-(5,6-二苯基吡 -2-基)-n-異丙基胺基]丁基氧基}-n-(甲基磺醯基)乙醯胺之醫藥組合物 | |
| JP2009534373A5 (cg-RX-API-DMAC7.html) | ||
| TW202412769A (zh) | Glp1錠劑組合物 | |
| WO2016051393A2 (en) | Crystalline form iv of trisodium supramolecular complex comprising valsartan and ahu-377 and methods thereof | |
| JP2018506535A5 (ja) | ネプリライシン阻害剤としての（２ｓ，４ｒ）−５−（５’−クロロ−２’−フルオロビフェニル−４−イル）−４−（エトキシオキサリルアミノ）−２−ヒドロキシメチル−２−メチルペンタン酸 | |
| JP2018507207A5 (cg-RX-API-DMAC7.html) | ||
| RU2018135072A (ru) | Кристаллическая (2s,4r)-5-(5'-хлор-2'-фтор-[1,1'-бифенил]-4-ил)-2-(этоксиметил)-4-(3-гидроксиизоксазол-5-карбоксамидо)-2-метилпентановая кислота и ее применения | |
| WO2009049495A1 (en) | Crystalline imidazol-5-carboxylic acid derivate | |
| RU2017132430A (ru) | (2r,4r)-5-(5′-хлор-2′-фторбифенил-4-ил)-2-гидрокси-4-[(5-метилоксазол-2-карбонил)амино]пентановая кислота | |
| CN110520425B (zh) | EOC315 Mod.I晶型化合物及其制备方法 | |
| CN103880829B (zh) | 一种阿齐沙坦晶体及其制备方法和用途 | |
| JP2013014547A (ja) | カンデサルタンシレキセチルを安定化した組成物及びその製造方法 | |
| JP2021512170A (ja) | Ｃｄｋ４／６キナーゼ阻害剤を標的とする結晶形 | |
| JP2008505935A5 (cg-RX-API-DMAC7.html) | ||
| CN104628708A (zh) | 一种阿伐那非的晶型及其制备方法、用途和药物组合物 | |
| US9364475B2 (en) | Tablet formulation of a phosphatidylinositol 3-kinase inhibitor | |
| CN106715404A (zh) | 无水结晶游离碱形式的6‑{2‑[1‑(6‑甲基‑3‑哒嗪基)‑4‑哌啶基]乙氧基}‑3‑乙氧基‑1，2‑苯并异噁唑 |